Zacks Investment Research upgraded shares of NantHealth (NASDAQ:NH) from a hold rating to a buy rating in a research report report published on Friday, reports. Zacks Investment Research currently has $0.75 price target on the stock.

According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “

Shares of NASDAQ NH opened at $0.64 on Friday. The company has a market capitalization of $70.36 million, a price-to-earnings ratio of -0.37 and a beta of 1.15. The company has a debt-to-equity ratio of 70.81, a quick ratio of 0.86 and a current ratio of 0.87. NantHealth has a 1-year low of $0.48 and a 1-year high of $3.64. The business’s 50 day moving average price is $0.60.

NantHealth (NASDAQ:NH) last announced its earnings results on Thursday, May 9th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.08). The firm had revenue of $23.73 million for the quarter, compared to the consensus estimate of $23.90 million. NantHealth had a negative return on equity of 405.21% and a negative net margin of 208.85%. On average, research analysts predict that NantHealth will post -0.53 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the stock. Miracle Mile Advisors LLC acquired a new stake in NantHealth during the first quarter worth approximately $27,000. SG Americas Securities LLC acquired a new stake in NantHealth during the fourth quarter worth approximately $29,000. Finally, Paloma Partners Management Co acquired a new stake in NantHealth during the fourth quarter worth approximately $31,000. 4.68% of the stock is currently owned by institutional investors and hedge funds.

NantHealth Company Profile

NantHealth, Inc, together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care. It develops NantHealth solutions, including molecular profiling solutions, software, and hardware systems infrastructure, which integrates patient data management, bioinformatics, and molecular medicine to enable value-based care and evidence-based clinical practice.

Read More: Analyst Ratings Trading

Get a free copy of the Zacks research report on NantHealth (NH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with's FREE daily email newsletter.